Drug development targeting the glycogen synthase kinase-3/β (GSK-3/β)-mediated signal transduction pathway: Inhibitors of the Wnt//β-catenin signaling pathway as novel anticancer drugs

Fumi Takahashi-Yanaga, Toshiyuki Sasaguri

Research output: Contribution to journalShort surveypeer-review

59 Citations (Scopus)

Abstract

Accumulating evidence suggests that the Wnt/β-catenin signaling pathway is often involved in oncogenesis and cancer development. Accordingly, a novel anticancer drug can be developed using inhibitors of this pathway. However, at present, there is no selective inhibitor of this pathway available as a therapeutic agent. Although all the components of the Wnt/β-catenin signaling pathway can be a target for drug development, glycogen synthase kinase-3? (GSK-3β), in particular, may be a good target because GSK-β? is an essential component of the pathway, and activation of this kinase results in the inhibition of the Wnt signaling pathway. We found that the differentiation-inducing factors (DIFs), putative morphogens for Dictyostelium discoideum, inhibit the Wnt/β-catenin signaling pathway via the activation of GSK-3β, resulting in the cell- cycle arrest of human cancer cell lines. In this review, we summarize our recent findings on the antiproliferative effect of DIFs and show the possibility for development of a novel anticancer drug from DIFs and their derivatives.

Original languageEnglish
Pages (from-to)179-183
Number of pages5
JournalJournal of Pharmacological Sciences
Volume109
Issue number2
DOIs
Publication statusPublished - 2009

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Fingerprint

Dive into the research topics of 'Drug development targeting the glycogen synthase kinase-3/β (GSK-3/β)-mediated signal transduction pathway: Inhibitors of the Wnt//β-catenin signaling pathway as novel anticancer drugs'. Together they form a unique fingerprint.

Cite this